Xenon Pharmaceuticals Inc.
XENE
Rank in Stocks
#4534
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Share Price
$34.95
Market Cap
$3.38B
Change (1 day)
4.36%
Change (1 year)
-16.05%
Country
CA
Trade Xenon Pharmaceuticals Inc. (XENE)
Category
Healthcare
P/S ratio for Xenon Pharmaceuticals Inc. (XENE)
P/S ratio as of October 2026 TTM: 0.00
According to Xenon Pharmaceuticals Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2023 the company had a P/S ratio of 0.00.
P/S ratio history for Xenon Pharmaceuticals Inc. from 2011 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | 253.04 | 242.30% |
| 2021 | 73.92 | 347.58% |
| 2020 | 16.52 | -66.83% |
| 2019 | 49.80 | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | 163.66 | 147.34% |
| 2016 | 66.17 | 797.61% |
| 2015 | 7.37 | -23.71% |
| 2014 | 9.66 | 177.11% |
| 2013 | 3.49 | 256.99% |
| 2012 | 0.98 | -51.58% |
| 2011 | 2.02 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
